Other studies, comparing AML sensitivities to various apoptogenic compounds with BH3 profiling and prosurvival BCL-2 family protein expression have confirmed that BH3 profiling is a valuable tool to predict apoptosis induction by some chemotherapy agents and targeted therapies. The gene discussed is BCL2; the disease is acute myeloid leukemia.